Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A

Total Valuation

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A carries a market capitalization of 9.49B, placing it among publicly traded companies globally. Its enterprise value stands at 10.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A currently has 3.00B shares outstanding.

Valuation Ratios

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 260.13. The price-to-sales ratio is 1.99, and the price-to-book ratio stands at 1.44.

Enterprise Valuation

On an enterprise value basis, Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 57.34 and an EV/FCF ratio of 28.96. The EV/Sales ratio of 1.90 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 57.34 provides insight into valuation relative to core operating earnings.

Financial Position

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A maintains a current ratio of 3.97, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.62, indicating elevated leverage, while an interest coverage ratio of 7.04 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A has paid 38.45M in income taxes, reflecting an effective tax rate of 49.40.

Stock Price Statistics

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A's stock has declined approximately -19.59288% over the past 52 weeks. The 50-day moving average sits at 3.22, while the 200-day moving average is 3.54.

Income Statement

Over the trailing twelve months, Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A generated 5.58B in revenue and converted that into -48.13M in net income, yielding earnings per share of -0.01. EBITDA reached 185.32M, while operating income came in at 185.32M.

Balance Sheet

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A holds 1.33B in cash and equivalents against 669.33M in total debt, resulting in a net debt position of -921.80M. Total book value stands at 7.74B, with working capital of 4.51B providing operational flexibility.

Cash Flow

After subtracting -187.28M in capital expenditures, free cash flow totaled -187.28M - equivalent to -0.06 per share.

Margins

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A operates with a gross margin of 52.00, reflecting its pricing power and cost economics. The operating margin of 3.32 and net profit margin of -0.86 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -319.30 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A's most recent stock split took place on October 26, 2016 with a 1:3 split ratio.

Scores

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A posts an Altman Z-Score of 5.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.